PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
26.85%
Revenue growth 1.25-1.5x MAXN's 18.89%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
97.18%
Gross profit growth under 50% of MAXN's 649.55%. Michael Burry would be concerned about a severe competitive disadvantage.
13.62%
EBIT growth below 50% of MAXN's 62.40%. Michael Burry would suspect deeper competitive or cost structure issues.
104.53%
Operating income growth above 1.5x MAXN's 62.40%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
136.23%
Net income growth above 1.5x MAXN's 10.77%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
136.36%
EPS growth above 1.5x MAXN's 10.74%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
127.27%
Diluted EPS growth above 1.5x MAXN's 10.74%. David Dodd would see if there's a robust moat protecting these shareholder gains.
6.93%
Share change of 6.93% while MAXN is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
9.44%
Diluted share change of 9.44% while MAXN is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
93.62%
OCF growth above 1.5x MAXN's 5.30%. David Dodd would confirm a clear edge in underlying cash generation.
76.88%
FCF growth similar to MAXN's 79.67%. Walter Schloss would attribute it to parallel capital spending and operational models.
-31.22%
Negative 10Y revenue/share CAGR while MAXN stands at 0.00%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-55.30%
Negative 5Y CAGR while MAXN stands at 0.00%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-46.50%
Negative 3Y CAGR while MAXN stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-101.54%
Negative 10Y OCF/share CAGR while MAXN stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-101.62%
Negative 5Y OCF/share CAGR while MAXN is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-100.43%
Negative 3Y OCF/share CAGR while MAXN stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
253.98%
10Y net income/share CAGR of 253.98% while MAXN is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
-96.52%
Negative 5Y net income/share CAGR while MAXN is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
101.80%
3Y net income/share CAGR of 101.80% while MAXN is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
-99.54%
Negative equity/share CAGR over 10 years while MAXN stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-99.43%
Negative 5Y equity/share growth while MAXN is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-99.08%
Negative 3Y equity/share growth while MAXN is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.30%
Firm’s AR is declining while MAXN shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-57.94%
Inventory is declining while MAXN stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
14.94%
Asset growth of 14.94% while MAXN is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
112.55%
BV/share growth of 112.55% while MAXN is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
1.93%
Debt growth of 1.93% while MAXN is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
13.42%
R&D dropping or stable vs. MAXN's 43.56%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
9.49%
SG&A growth well above MAXN's 9.84%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.